HopeStage
Back to all studies
CompletedNCT05657691

Xanamem in depression with cognitive difficulties

Researchers studied Xanamem’s effects on depressive and cognitive symptoms, alongside its safety and tolerability.

MedicationAges 18–75Australia + United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations
Blacktown and 11 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: November 28, 2022
Recruitment status
Completed
Enrollment listed in the registry
167
Sponsor
Actinogen Medical
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Australia, United Kingdom
Age range
From 18 Years to 75 Years
Official registry ID
NCT05657691
Official title
Show the full official title

XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Blacktown, Australia · Newcastle, Australia · Brisbane, Australia

7 more locations
  • Sippy Downs, Australia
  • Melbourne, Australia
  • Noble Park, Australia
  • London, United Kingdom
  • Manchester, United Kingdom
  • Motherwell, United Kingdom
  • Tankersley, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Actinogen Medical.

Did this study involve medication?

Yes. The study involved medication, including Xanamem™ and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies